Wegovy (Semaglutide) Cuts Heavy Drinking in First-of-Its-Kind Randomized Alcohol Addiction Trial

A landmark Danish randomized clinical trial published in The Lancet on May 4, 2026, has provided the first high-quality, placebo-controlled clinical evidence that Wegovy (semaglutide 2.4 mg) significantly reduces heavy drinking in adults with moderate-to-severe alcohol use disorder (AUD) and comorbid obesity.

The trial is a significant milestone because it is the first randomized controlled trial (RCT) to test semaglutide in treatment-seeking patients in a real-world setting, rather than a laboratory environment, validating years of anecdotal and observational reports.

Key Trial Results

• Primary Endpoint (Heavy Drinking Days): Over 26 weeks, adults receiving a weekly 2.4-mg subcutaneous dose of semaglutide alongside cognitive behavioral therapy (CBT) experienced a 41.1-percentage-point reduction in heavy drinking days, compared to a 26.4-percentage-point drop for those on placebo (p = 0.0015).
• Overall Consumption: Semaglutide-treated patients showed a significantly greater reduction in pure alcohol intake over a 30-day period compared to placebo (-1,550.2 g vs. -1,025.9 g), which equates to roughly 111 fewer standard drinks for the semaglutide group versus 74 fewer standard drinks for the placebo group.
• Craving and Risk Reductions: Participants on Wegovy experienced greater improvements in the Penn Alcohol Craving Scale (-9.2 vs. -6.1) and a substantial reduction in World Health Organization (WHO) risk drinking levels (-1.75 vs. -1.24).
• Liver Health Biomarkers: Biomarker analyses showed highly favorable changes in liver health markers, including plasma phosphatidylethanol and γ-glutamyl transferase (GGT).
• Tolerability: The most common adverse events were gastrointestinal, including nausea (57% on semaglutide vs. 7% on placebo), vomiting (15% vs. 2%), and constipation (35% vs. 17%).

Market and Clinical Implications

According to George Koob, PhD, director of the NIH's National Institute on Alcohol Abuse and Alcoholism (NIAAA), current FDA-approved pharmacotherapies for AUD (disulfiram, acamprosate, and naltrexone) are "vastly underutilized." A highly effective and widely accessible option like semaglutide could close a massive treatment gap.

"A new option that is more accessible and more effective could be a game-changer for closing the treatment gap." — George Koob, PhD, Director of the NIH's National Institute on Alcohol Abuse and Alcoholism

For pharmaceutical companies and investors, these results provide a concrete clinical foundation for expanding the reimbursement and labeling of GLP-1 receptor agonists into psychiatric and addiction medicine. This significantly expands the addressable market size beyond metabolic health, paving the way for formal FDA label expansions for alcohol use disorder and other substance use disorders.